A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: Preliminary observations [7]

Gut

Volumn 55, Issue 6, 2006, Pages 901-902

  Federico, A ^a   Trappoliere, M ^a   Tuccillo, C ^a   De Sio, I ^a   Di Leva, A ^a   Del Vecchio Blanco, C ^a   Loguercio, C ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ASPARTATE AMINOTRANSFERASE; B LYMPHOCYTE GROWTH FACTOR; FLAVONOID; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HYALURONIC ACID; INSULIN; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; SILIBININ;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIOXIDANT ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CONTROLLED STUDY; DRUG CONJUGATION; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTYPE; HEPATITIS C; HISTOLOGY; HUMAN; INFORMED CONSENT; INSULIN RESISTANCE; LETTER; LIVER DISEASE; LIVER INJURY; MAJOR CLINICAL STUDY; NON ALCOHOLIC FATTY LIVER DISEASE; OUTPATIENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

DRUG COMBINATIONS; FATTY LIVER; HUMANS; INSULIN RESISTANCE; PHOSPHOLIPIDS; SILYMARIN; VITAMIN E;

EID: 33646770979     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.091967     Document Type: Letter

References (9)

1. Patrick L. Hepatitis C. Epidemiology and review of complementary/ alternative medicine treatments. Altern Med Rev 1999;4:220-38.
2. Younossi ZM, McCullough AJ, Ong JP, et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol 2004;38:705-9.
3. Bean P. The use of alternative medicine in the treatment of hepatitis C. Am Clin Lab 2002;21:19-21.
4. Zhao J, Agarwal R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Carcinogenesis 1999;20:2101-8.
5. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001;21:3-16.
6. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
7. Melchionda N, Forlani G, Marchesini G, et al. WHO and ADA criteria for the diagnosis of diabetes mellitus in relation to body mass index. Insulin sensitivity and secretion in resulting subcategories of glucose tolerance. Int J Obes Reht Metab Disord 2002;26:90-6.
8. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127:1704-13.
9. Joseph AE, Saverymuttu SH, al-Sam S, et al. Comparison of liver histology with ultrasonography in assessing diffuse parenchimal liver disease. Clin Radial 1991;9:91-4.